4 – Alzheimers

Four months before a best-selling Alzheimer's drug was set to lose its patent protection, its makers received approval for a higher dosage that extended their exclusive right to sell the drug. But the higher dosage caused potentially dangerous side effects and worked only slightly better than the existing drugs, according ... continue reading

Elan Corp. Plc and Transition Therapeutics Inc. said Tuesday they’ve eliminated two of three doses used in a mid-stage study of a potential Alzheimer’s disease treatment after nine patients died while receiving the higher doses.

Read more:
... continue reading